Oral contraceptives may influence the risk of certain cancers. As part of the AHRQ Evidence
Report, Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer, we conducted …

Purpose To estimate the risks of ovarian cancer and breast cancer associated with oral
contraceptive (OC) use among women at elevated risk owing to mutations in BRCA1/2 or a …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Summary The 2024 US Medical Eligibility Criteria for Contraceptive Use (US MEC)
comprises recommendations for the use of specific contraceptive methods by persons who …

Summary The 2016 US Medical Eligibility Criteria for Contraceptive Use (US MEC)
comprises recommendations for the use of specific contraceptive methods by women and …

Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for
use of contraception, offering guidance on the safety and use of different methods for women …

The need to seek improved combined oral contraceptive (COC) efficacy, with fewer health
risks and better acceptability, has been ongoing since the introduction of COCs more than …

BACKGROUND Fear from increased cancer risk is one of the most significant reasons for
low acceptance of reliable contraceptive methods and low compliance. METHODS In this …

BRCA1 and BRCA2 mutations increase breast and ovarian cancer risks substantially
enough to warrant risk reduction surgery, despite variable risk estimates. Underlying this …

Purpose Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer;
options to reduce cancer mortality include prophylactic surgery or breast screening, but their …